Pet Owners Are Self-Administering 'Wolverine Stack' Peptides to Their Dogs

A growing cohort of dog owners — ranging from budget-strapped pet parents to high-end wellness devotees — are injecting their animals with the same unregulated peptide compounds they use on themselves, particularly BPC-157 and TB-500, a combination dubbed the 'Wolverine stack' in fitness circles. The trend has exploded in part because the peptides are cheap (often under $100 for a month's supply) compared to conventional veterinary treatments, and because anecdotal human results have been striking enough that owners see little reason not to extend the experiment to their pets.

The poster dog for the movement is Choo Choo, a 14-year-old pit terrier owned by Florida personal trainer Michael Morelli, who began giving the dog BPC-157 and TB-500 roughly a year ago when Choo started struggling to finish half-mile walks. Morelli — who takes the same peptides himself and credits them with resolving a shoulder injury — says Choo began running and playing again within two to three weeks. Morelli started at 500 micrograms and gradually increased to 2 milligrams, with no established safe or effective dose for dogs to guide him. His niche experiment got massive amplification in July when podcast star Andrew Huberman told his 1.8 million followers on X that he was hearing of 'amazing results' from pet owners using BPC-157 — after which Morelli's following exploded and he launched a canine longevity brand called Pawgen.

Veterinarians are watching uneasily. Dr. Leilani Alvarez of New York's Schwarzman Animal Medical Center says clients are asking her about unapproved peptides but that she would be 'very cautious' about BPC-157 specifically. The biggest red flag: the peptide appears to stimulate blood vessel growth, a mechanism that could theoretically feed existing tumors or generate new ones. Celine Halioua, CEO of dog-longevity startup Loyal, called the cancer risk a 'dealbreaker' and urged anyone experimenting anyway to work with a vet to monitor for invisible side effects. No controlled long-term clinical studies in dogs exist to resolve the question.

The stakes became painfully concrete for Dallas-based project manager Ryan Samluk, 29, who spent about $160 on KPV and BPC-157 for his 11-year-old Australian-German Shepherd mix, Finley, after a devastating sprain he couldn't afford to treat conventionally at $200 per arthritis shot. He based the dosing on human guidelines adjusted for Finley's weight. Within a week, he says, she was running. Weeks later, Finley was diagnosed with hemangiosarcoma, an aggressive blood cancer with a prognosis of a few months. The cancer almost certainly predated the peptide shots — but the timing underscores why veterinarians want clinical data before widespread adoption. Meanwhile, the longevity-obsessed and the financially stretched are converging on the same gray-market solution, and the guardrails remain essentially nonexistent.